Two new terms needed in the management of advanced prostate cancer

It is rapidly becoming apparent that we are going to need two simple, new terms to be able to use in discussion of the evolution of progressive prostate cancer after “standard” forms of androgen deprivation therapy (ADT) have failed to work. So … anyone got good, scientifically sound suggestions? … READ MORE …

Regeneron to continue VENICE trial of aflibercept

According to a media release from Regeneron Pharmaceuticals, the company plans to continue the randomized, multi-center, Phase III VENICE clinical trial, designed to evaluate the efficacy and safety of aflibercept (ZALTRAP™) in combination with docetaxel in the first-line treatment of patients with metastatic, hormone-refractory prostate cancer. … READ MORE …

A quick update on Apoptone in hormone-refractory prostate cancer

Back in 2008 we first mentioned the initiation of clinical trials of a drug called Apoptone or HE3235 in men with hormone-refractory prostate cancer. Data on the development of Apoptone was another item on the agenda at the annual meeting of the American Society of Clinical Oncology (ASCO) earlier this week. … READ MORE …

The conversation behind the scenes at ASCO

At major medical meetings like the recent AUA and ASCO annual meetings (the latter wrapping up today in Chicago), what goes on in the conversations in the corridors and in private meetings is often more important and interesting than what is being presented from the podium or talked about at poster sessions. … READ MORE …

The next generation of hormonal therapies for prostate cancer

Beyond abiraterone acetate and MDV3100 and even TAK-700, a new generation of treatments for hormonally driven cancers like prostate cancer (and breast cancer) is being explored by start-up companies like Aragon Pharmaceuticals. … READ MORE …

Prostate cancer news reports: Sunday, August 2, 2009

Only two news reports of any significance this weekend, on:

  • Pesticides and prostate cancer risk in Martinique
  • The transition from hormone-sensitive to hormone-refractory disease … READ MORE …

The prostate cancer news for Thursday, July 30

News items today are focused on information about:

  • a new way of approaching treatment of hormone-refractory disease
  • the initial clinical trials of a new drug candidate in hormone-refractory patients
  • the association between hospital and surgeon volume and patient outcomes after radical prostatectomy. … MORE …

Prostate cancer news update, PART B: Tuesday, July 28

Here is Part B of your daily prostate cancer news update. Unless someone announces a cure for prostate cancer we will probably hold any further news until tomorrow! … MORE …

Your prostate cancer news “fix” for Monday, July 27th

In today’s prostate cancer news:

  • More on the effects of hormone therapy on cognitive function and
  • The application to market satraplatin has been withdraw in Europe … MORE …

The abiraterone acetate media feeding frenzy

For some reason, the major media have decided that abiraterone acetate is “a wonder drug” that is going to solve all of the problems of men with hormone refractory prostate cancer and maybe more. The following is a quotation from a story in today’s Los Angeles Times: … MORE …